OREANDA-NEWS.Now in its 21st year, IBT is a specialist investor in biotechnology companies globally. In the year ended February 2015, it returned c 50% in NAV and 49% in share price terms, ahead of the Nasdaq Biotechnology Index's 39% return. IBT is differentiated from its peers by its holdings in unquoted stocks (c 8% at present), a part of the portfolio that has recently contributed to the Trust's strong performance, reflecting successful exits and a milestone payment. The long-term growth drivers for the biotech sector remain in place and the Investment Managers expect strong sector earnings growth to outpace market growth over the long-term.
Rate this article: